TipRanks
Exelixis (DE:EX9)
FRANKFURT:EX9
Germany Market
EX9
Exelixis
RESEARCH TOOLSreports

Exelixis (EX9) Stock News & Sentiment

1 Followers
Exelixis Rated Hold as Zanzalintinib CRC Outlook Remains Mixed; $54 Price Target Reaffirmed
Premium
Ratings
Exelixis Rated Hold as Zanzalintinib CRC Outlook Remains Mixed; $54 Price Target Reaffirmed
20d ago
EXEL
FDA-Driven Zanza Delay Keeps Exelixis Fairly Valued, Supporting Willey’s Hold Rating
Premium
Ratings
FDA-Driven Zanza Delay Keeps Exelixis Fairly Valued, Supporting Willey’s Hold Rating
22d ago
EXEL
FDA Extends Review Timeline for Exelixis Cancer Drug
Premium
Company Announcements
FDA Extends Review Timeline for Exelixis Cancer Drug
23d ago
8K
EXEL
Exelixis Secures Key Patent Victory, Extends Exclusivity
Premium
Company Announcements
Exelixis Secures Key Patent Victory, Extends Exclusivity
1M ago
8K
EXEL
Exelixis Earnings Call: Cabo Strength, Zanza Awaited
Premium
Company Announcements
Exelixis Earnings Call: Cabo Strength, Zanza Awaited
2M ago
EXEL
Exelixis Targets Residual Colorectal Cancer With New Phase 3 Trial
Premium
Company Announcements
Exelixis Targets Residual Colorectal Cancer With New Phase 3 Trial
2M ago
EXEL
Exelixis: Buy Rating Reaffirmed on Cabozantinib Resilience, Cost Discipline and Zanzalintinib Upside Despite Near-Term NET Guidance Cut
Premium
Ratings
Exelixis: Buy Rating Reaffirmed on Cabozantinib Resilience, Cost Discipline and Zanzalintinib Upside Despite Near-Term NET Guidance Cut
2M ago
EXEL
More DE:EX9 News >

EX9 News on the Web

Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
Zacks
Neutral
Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?
Insider Monkey
Neutral
Exelixis Inc at Morgan Stanley Global Healthcare Conference Transcript
GuruFocus News
Neutral
FDA-Driven Zanza Delay Keeps Exelixis Fairly Valued, Supporting Willey’s Hold Rating
TipRanks News
Neutral
Analysts’ Opinions Are Mixed on These NA Stocks: SpaceX (SPCX), Insmed (INSM) and Exelixis (EXEL)
TipRanks News
Bearish
Exelixis Inc at Citi Biopharma Back to School Summit Transcript
GuruFocus News
Neutral
Exelixis Inc at Wells Fargo Healthcare Conference Transcript
GuruFocus News
Neutral
Exelixis Secures Key Patent Victory, Extends Exclusivity
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
DE:EX9
Sector Average
Media Buzz
This Week3 articles
Weekly Average6.25 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:EX9’s Media Buzz Sentiment?
3 articles about DE:EX9 were published this week. In an average week, 6.25 articles are published.
    What is DE:EX9’s weekly average amount of articles?
    In an average week, 6.25 articles about DE:EX9 are published.
      What is DE:EX9’s News Sentiment?
      100% of articles about DE:EX9 were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        RHHBYRoche Holding
        BAYRYBayer
        SNYSanofi
        CICigna
        TFXTeleflex
        Showing the stocks with the most bullish news sentiment over the past week